
- Powerpoint 2016 for free bcps full#
- Powerpoint 2016 for free bcps software#
- Powerpoint 2016 for free bcps trial#
- Powerpoint 2016 for free bcps plus#
6 As a result, DOAC prescriptions exceeded those for warfarin by 2013, with apixaban being the most frequently prescribed DOAC for patients with nonvalvular atrial fibrillation (NVAF). 2, 3, 4, 5 Advantages of DOACs compared with VKAs include fewer monitoring requirements, less frequent follow‐up, more immediate drug onset and offset effects (important for periprocedural and acute bleeding management), and fewer drug and food interactions. DOACs are relatively new agents demonstrating superiority or noninferiority to prior standards of care, anticoagulation with vitamin K antagonists (VKA ie, warfarin), or low‐molecular‐weight heparins (LMWHs), in reducing risk of thromboembolic complications with similar or reduced bleeding risk. In 2010, the US Food and Drug Administration (FDA) approved its first DOAC, dabigatran, followed by rivaroxaban, apixaban, edoxaban, and betrixaban in the following years. 1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie, rivaroxaban, apixaban, edoxaban, and betrixaban) and direct thrombin inhibitors (ie, dabigatran). Nonstandard Abbreviations and Acronyms AFĭirect oral anticoagulants (DOACs)-dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. Topics addressed include (1) appropriate indications (2) use in patients with specific comorbidities (3) monitoring parameters (4) transitioning between anticoagulant regimens (5) major drug interactions and (6) cost considerations. This review will provide an overview of DOACs and act as a practical reference for clinicians to optimize DOAC use among common challenging scenarios. With the expanding role of DOACs, clinicians are faced with increasingly complex decisions relating to appropriate agent, duration of treatment, and use in special populations. Since the first approval in 2010, DOACs have emerged as leading therapeutic alternatives that provide both clinicians and patients with more effective, safe, and convenient treatment options in thromboembolic settings. DOACs are indicated for prevention and treatment of several cardiovascular conditions.

Powerpoint 2016 for free bcps plus#
Powerpoint 2016 for free bcps software#
A Microsoft Office 2016 product key activates the software to its premium version. Luckily, you can find a free genuine Microsoft Office 2016 product key online.
Powerpoint 2016 for free bcps full#
After activating your version of Microsoft office you can avail full features of any of the Office 2016 applications including Microsoft Word 2016, Excel 2016, Outlook 2016 and PowerPoint 2016.
Powerpoint 2016 for free bcps trial#
Microsoft Office 2016 activation keys or product key can be used to activate your trial or limited edition of Office 2016 suite.

Microsoft office 2016 is amongst the world’s most widely used text processor.
